CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Magnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux

This policy governs coverage and medical necessity determinations for laparoscopic magnetic esophageal sphincter augmentation (eg, LINX device) to treat gastroesophageal reflux disease (GERD) for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMagnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2017

Next Review DateN/A

Key ActionVerify member-specific benefits and contact the provider call center for coverage prior to treatment.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance

FDA-approvedRegulatory status

2017–2023Effective / last update

43284Not covered code

Coverage determination and policy scope

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered / Not medically necessary

Covered when ALL of the following are met:

Primary coverage stance: Magnetic esophageal sphincter augmentation to treat gastroesophageal reflux disease is not covered because the evidence is insufficient to determine the effects of the technology on health outcomes.

Applies to Commercial Products and Medicare Advantage; procedure code 43284 is listed as not covered / not medically necessary.

Benefits and eligibility for services described in this policy may vary by group contract. Refer to the member's Benefit Booklet, Evidence of Coverage, Subscriber Agreement, or employer agreement to determine coverage for services that are not medically necessary or not covered. For member-specific benefit questions, contact the provider call center prior to treatment.

If services are determined to be not medically necessary or are non‑covered benefits under the member's contract, providers may not bill the member for those services unless the provider has obtained the member's informed written agreement in advance to accept financial responsibility.

For Commercial Products, magnetic esophageal sphincter augmentation (MSA) to treat gastroesophageal reflux disease is considered not medically necessary because the evidence is insufficient to determine effects on health outcomes. As stated in this policy, the procedure is not covered and the relevant procedure code 43284 is listed as not covered/not medically necessary.

Although the LINX Reflux Management System holds FDA approval, for Commercial Products the clinical evidence available to support routine coverage and favorable health outcomes is inadequate; therefore placement of the device is excluded from coverage under this policy for Commercial members.

Procedure and regulatory coding details

Not covered / Not medically necessary procedure codesCPTNot Covered

43284

Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed

FDA follow-up requirement — LINX (MSA) PMA details

Regulatory pathwayFDA approved via Premarket Approval (PMA) in 2012 for patients with abnormal pH and persistent GERD symptoms despite maximum therapy.

Initial post‑approval requirementFDA initially required 5‑year follow‑up of 100 patients from the pivotal investigational device exemption study to evaluate safety and efficacy; follow‑up was completed in March 2016.

FDA product codeLEI

Manufacturer (as listed in approval)Torax Medical (Shoreview, MN)

What providers must do

Prior Authorization

Prior authorization / benefit verification

This policy does not require a prior authorization at the policy level, but benefits and coverage may vary by group and contract; providers should verify member-specific coverage before scheduling services.

Note

Clinical positioning relative to medical therapy

The policy states MSA (LINX) is intended for patients with persistent GERD symptoms despite maximum medical therapy (eg, proton pump inhibitors); however, the technology is not covered because evidence is insufficient to determine effects on health outcomes.

Documentation Required

Confirm member benefits

Confirm member benefits by reviewing the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement and contact the provider call center for member-specific benefit information prior to treatment.

Do not assume coverage; verify benefits for services deemed not medically necessary/not covered.
Contact the provider call center for member-specific questions.

Denial Risk

Denial risk for MSA (LINX) placement (CPT 43284)

Claims submitted with CPT code 43284 (laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device) are at risk of denial because the policy designates the procedure as not covered/not medically necessary.

Do not bill the member for services determined to be not medically necessary unless there is a prior written agreement.
Verify alternative coverage or obtain prior written agreement before performing the procedure.

Clinical background

Gastroesophageal reflux disease (GERD) is the reflux of stomach acid into the esophagus that produces symptoms and/or mucosal injury, with a clinical spectrum ranging from mild intermittent heartburn to chronic, severe disease with complications.

The LINX system (magnetic sphincter augmentation) is a laparoscopically implanted flexible band of interlinked magnetic titanium beads placed at the gastroesophageal junction to augment the lower esophageal sphincter. It is proposed as an alternative for patients with persistent GERD symptoms despite maximal medical therapy, but device‑related adverse events (for example, dysphagia, device erosion, need for removal) and other factors affect its risk/benefit profile.

Device definition

Magnetic sphincter augmentation (MSA) / LINX — device and placement

Device descriptionA small flexible band of 10–18 interlinked titanium beads with magnetic cores placed around the esophagus at the gastroesophageal junction to augment the lower esophageal sphincter.

Placement techniquePlaced laparoscopically around the esophagus at the level of the gastroesophageal junction using standard laparoscopic techniques; may be removed laparoscopically if needed.

Mechanism of actionMagnetic attraction between beads augments the lower esophageal sphincter to prevent reflux while allowing expansion during swallowing as beads separate under pressure.

Intended populationPatients with GERD who have persistent symptoms despite maximum medical therapy (eg, PPIs) seeking an alternative to fundoplication.

Potential adverse events / considerationsAdverse events may include dysphagia or odynophagia; device removal may be required for severe events or to permit MRI.